{"id":11568,"date":"2024-06-27T01:53:48","date_gmt":"2024-06-27T01:53:48","guid":{"rendered":"https:\/\/economicherald.net\/?p=11568"},"modified":"2024-06-27T01:53:48","modified_gmt":"2024-06-27T01:53:48","slug":"asx-health-stocks-immutep-sinks-35pc-despite-positive-results-from-cancer-treatment-trial","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=11568","title":{"rendered":"ASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial"},"content":{"rendered":"

Immutep sinks 35pc despite positive TACTI-003 Phase IIb trial results
\nInvestors may have had higher expectations, leading to the market reaction
\nThe trial evaluated efti with KEYTRUDA for first-line head and neck cancer<\/p>\n

\u00a0<\/p>\n

Immutep (ASX:IMM)<\/a><\/strong> plunged 35% this morning after releasing its topline results from the TACTI-003 Phase IIb Trial<\/strong> in First Line Head and Neck Cancer.<\/p>\n

The overall results were positive so there was no clear reason for the selloff. One reason could be that investors may have had higher expectations for the trial results.<\/p>\n

The TACTI-003 Phase IIb trial evaluated the effectiveness of eftilagimod alfa (efti)<\/strong>, in combination with KEYTRUDA (pembrolizumab)<\/strong> for treating first-line head and neck squamous cell carcinoma (HNSCC).<\/p>\n

This clinical trial represents a pivotal step forward in cancer treatment, particularly for recurrent or metastatic forms of HNSCC.<\/p>\n

The primary focus of the trial was to assess how efti, Immutep\u2019s proprietary soluble LAG-3 protein and MHC Class II agonist, performs alongside KEYTRUDA, a well-established anti-PD-1 therapy from Merck & Co.<\/p>\n

The results revealed that the combination therapy significantly outperformed KEYTRUDA monotherapy across various levels of PD-L1 expression.<\/p>\n

Notably, patients with high PD-L1 expression (CPS >20) exhibited an overall response rate (ORR) of 31.0%, compared to 18.5% with KEYTRUDA alone in the randomised Cohort A of the trial.<\/p>\n

In Cohort B, which focused on patients with negative PD-L1 expression (CPS <1), the response rate saw an improvement from earlier assessments, reaching levels that have been accepted for presentation at an upcoming ESMO Virtual Plenary<\/em> session.<\/p>\n

This underscores the potential of the efti and KEYTRUDA combination to offer viable treatment options for patient groups who currently lack effective chemotherapy-free alternatives.<\/p>\n

Dr. Martin Forster, an investigator involved in the trial, noted efti\u2019s consistent efficacy across varying PD-L1 expression levels and HPV (human papillomavirus) status.<\/p>\n

\u201cThe strong, consistent response rates, irrespective of whether patients have high, low, or negative PD-L1 expression, is intriguing and offers a glimpse into this novel combination\u2019s ability to improve patients\u2019 clinical responses and expand patient populations that benefit from anti-PD-1 therapy.\u201d<\/p>\n

Building on these positive findings, Immutep now plans to engage with regulatory agencies to discuss potential pathways forward for treating metastatic first-line HNSCC patients.<\/p>\n

Efti is a special protein developed by Immutep to help the immune system fight cancer better.<\/p>\n

It works by activating certain immune cells called antigen presenting cells (APCs), which then boost the activity of other immune cells like cytotoxic T cells, helper T cells, dendritic cells, NK cells, and monocytes.<\/p>\n

This activation helps the immune system produce important molecules like IFN-\u03b3 and CXCL10, which are crucial in fighting cancer.<\/p>\n

\u00a0<\/p>\n\n

\u00a0<\/p>\n

\ufeff<\/span><\/span>\u00a0<\/p>\n

The post ASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial<\/a> appeared first on Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

Immutep sinks 35pc despite positive TACTI-003 Phase IIb trial results Investors may have had higher expectations, leading to the market reaction The trial evaluated efti [more…]<\/a><\/p>\n","protected":false},"author":0,"featured_media":11569,"comment_status":"","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-11568","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"\nASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=11568\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Immutep sinks 35pc despite positive TACTI-003 Phase IIb trial results Investors may have had higher expectations, leading to the market reaction The trial evaluated efti [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=11568\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-27T01:53:48+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11568#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11568\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial\",\"datePublished\":\"2024-06-27T01:53:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11568\"},\"wordCount\":460,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11568#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Immutep-sinks-despite-reporting-solid-topline-results-from-Phase2b-trial.-Picrure-Getty-u2Riku.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11568\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=11568\",\"name\":\"ASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11568#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11568#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Immutep-sinks-despite-reporting-solid-topline-results-from-Phase2b-trial.-Picrure-Getty-u2Riku.jpeg\",\"datePublished\":\"2024-06-27T01:53:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11568#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=11568\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11568#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Immutep-sinks-despite-reporting-solid-topline-results-from-Phase2b-trial.-Picrure-Getty-u2Riku.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Immutep-sinks-despite-reporting-solid-topline-results-from-Phase2b-trial.-Picrure-Getty-u2Riku.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11568#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=11568","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial - Economic Herald","og_description":"Immutep sinks 35pc despite positive TACTI-003 Phase IIb trial results Investors may have had higher expectations, leading to the market reaction The trial evaluated efti [more...]","og_url":"https:\/\/economicherald.net\/?p=11568","og_site_name":"Economic Herald","article_published_time":"2024-06-27T01:53:48+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=11568#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=11568"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial","datePublished":"2024-06-27T01:53:48+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=11568"},"wordCount":460,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=11568#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/Immutep-sinks-despite-reporting-solid-topline-results-from-Phase2b-trial.-Picrure-Getty-u2Riku.jpeg","articleSection":["Finance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=11568","url":"https:\/\/economicherald.net\/?p=11568","name":"ASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=11568#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=11568#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/Immutep-sinks-despite-reporting-solid-topline-results-from-Phase2b-trial.-Picrure-Getty-u2Riku.jpeg","datePublished":"2024-06-27T01:53:48+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=11568#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=11568"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=11568#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/Immutep-sinks-despite-reporting-solid-topline-results-from-Phase2b-trial.-Picrure-Getty-u2Riku.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/Immutep-sinks-despite-reporting-solid-topline-results-from-Phase2b-trial.-Picrure-Getty-u2Riku.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=11568#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/11568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11568"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/11568\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/11569"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}